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analysis included the effect of the at-risk polymorphism on postbronchodilator lung function.
Results: There was an interaction between asthma status and the PAI-1 polymorphism on FEV 1 /FVC (P=.03). The gain-of-function variants, genotypes (AA/AG), were associated with lower FEV 1 /FVC in subjects with asthma (b=À1.25, CI:
À2.14,À0.35, P=.006), but not in controls. Subjects with asthma and the AA/AG genotypes had a 5% decrease in FEV 1 /FVC (P<.001). In asthmatics, the risk genotype (AA/AG) was associated with a 39% increase in risk of clinically relevant airway obstruction (OR=1.39, CI: 1.01, 1.92, P=.04). These associations persisted after exclusion of factors that increase PAI-1 including tobacco exposure and obesity.
Conclusions and Clinical Relevance:
The decrease in the FEV 1 /FVC ratio associated with the risk genotype was modified by asthma status. The genotype increased the odds of airway obstruction by 75% within asthmatics only. As exposures known to increase PAI-1 levels did not mitigate this association, PAI-1 may contribute to airway obstruction in the context of chronic asthmatic airway inflammation.
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| INTRODUCTION
Urban minority children are more likely than white children to have asthma and reduced lung function. 1, 2 Genetic and environmental factors contribute to decreased lung function in this group. While lower socio-economic status (SES) is correlated with decreased pulmonary function in children and with greater rates of decline in adulthood, [2] [3] [4] [5] genetic ancestry is associated with lung function 6 in admixed populations even after accounting for SES. 7 These genetic associations may be population specific 8 or dependent on environmental factors to affect lung disease and phenotypes. 9, 10 We recently studied a gainof-function polymorphism in PAI-1, which is a variant whose frequency varies by African ancestry. 11 We found a joint effect of the PAI-1 polymorphism at the rs2227631 promoter region and early life infection, which was associated with reduced FEV 1 and FEV 1 /FVC ratio in children with asthma. 10 While there are a few studies of the association of PAI-1 and lung function in children with asthma, 12 there are no studies in generally healthy children without asthma and therefore without ongoing airway inflammation. This is a biologically relevant question as plasminogen activator inhibitor 1 (PAI-1) is important in deposition of extracellular matrix and airway remodelling after lung injury. 13, 14 It is also unclear as to whether genotype associations with lung function would persist after accounting for environmental factors such as smoke exposure, obesity and early viral illnesses, which are prevalent in urban minority populations, [15] [16] [17] [18] and all of which increase PAI-1 levels. [19] [20] [21] [22] Further, evaluating the role of factors which affect PAI-1 levels may be particularly important for urban minority Latino Americans who have approximately 65% higher PAI-1 protein levels compared to African
Americans and non-Latino Caucasians. 23, 24 We sought to determine whether the association of a gain-offunction PAI-1 mutation with airway obstruction is modified by asthma status in Latino children in the Genes-environments & Admixture in Latino Americans (GALA II) cohort. We also sought to determine whether the associations of the polymorphism persist after controlling for common chronic stimuli known to increase PAI-1 levels including secondhand smoke exposure and obesity. We hypothesized that there would be an interaction between asthma status and the PAI-1 gain-of-function polymorphism on the outcome of airway obstruction, such that an association would be present in asthmatics only. We also hypothesized that this effect would be present even after controlling for common childhood exposures that are associated with elevated PAI-1 levels.
| MATERIALS AND METHODS

| Subjects
The participants of this study were a population of Latino children enrolled as a part of the GALA II study. Females were ineligible if they were in the third trimester of pregnancy. Asthma was defined as having both a history of physician diagnosed asthma and a self-reported presence of coughing, wheezing, or shortness of breath in the 2 years preceding enrolment. For this analysis, subjects were included based on availability of lung function parameters (outlined below), and PAI-1 genotyping for rs2227631, resulting in an analytic sample of 2070 subjects.
| PAI-1 genotyping for rs2227631
Genomewide genotyping was performed with the Axiom array as previously described. 25 The A allele within the SNP promoter site, rs2227631, for PAI-1 is a gain-of-function mutation that associates with higher PAI-1 plasma levels and is included in this analysis. In an exploratory analysis, we evaluated the individual associations of AG and AA genotypes on lung function (FEV 1 , FVC, FEV 1 /FVC ratio). Preliminary results indicated a correlation between the promoter mutation and lung function, particularly on the FEV 1 /FVC ratio. The AG and AA groups were combined for primary analysis to increase precision of estimates even if these estimates would be more conservative.
Notably, there was a clear dose effect for the A allele that remained statistically significant in our prior paper. 10 This was also noted in our current sensitivity analyses for the relative associations of the AA and AG genotypes on the FEV 1 /FVC ratio (data not shown).
| Lung function parameters
The lung function parameters of forced expiratory volume in 1 sec- according to the NAEPP guidelines. 27 
| Exposures
Obesity-Study participants underwent weight and height measurements using standardized techniques and equipment during study recruitment. Body mass index (BMI) was calculated and categorized by percentile using standardized childhood sex-and age-specific growth charts (http://www.cdc.gov/nccdphp/dnpao/growthcharts/ resources/sas.htm). Subjects with a BMI<5th percentile were classified as underweight, >5th and <85th percentile were classified as healthy weight, the 85th-94th percentile were considered overweight, and ≥95th percentile were classified as obese. 28 For the purposes of this analysis, subjects were classified as underweight, asthma. 29 Data regarding the at-risk polymorphism, relevant covariates, and lung function were available for all included subjects.
| Statistical analysis
Baseline characteristics of participants of asthmatic and non-asthmatic subjects included in this analytic sample were compared using t tests and chi-square tests. We first carried out linear regression on the population to determine the association of the at-risk genotype with lung function. We then tested the interaction term for genotype and asthma in the same model, retaining the primary variables for asthma and genotype. Following this, linear regression models were performed stratified by asthma status to determine the effect of the mutation on lung function parameters.
All multivariate linear regressions included the following confounders: respiratory illness before age of two, household income, inhaled corticosteroid use, African and European ancestry, and site.
Sex, ethnicity, and age are adjusted for within the per cent predicted scores used within the analyses for lung function parameters; therefore, they were not included as confounders in the linear regression model. Logistic regression analysis stratified by asthma status was used to determine whether having the rs2227631 gainof-function polymorphism was associated with increased risk of clinical obstruction. These analyses controlled for potential confounders including household income, inhaled corticosteroid use, African and European ancestry, and site. Again, sex, ethnicity, and age are incorporated within the per cent predicted FEV 1 /FVC ratio and were not included as confounders. Due to no subjects with the wild-type genotype having obstruction, we carried out a
Fisher's exact test for obstruction in non-asthmatic subjects, but are not able to estimate an odds ratio.
To determine whether key mediators (maternal obesity, pre-and postnatal smoke exposure, and respiratory illness prior to age two) mitigated any association between the at-risk genotype and lung function parameters, we included these serially and then in combination in the baseline linear regression model described above for lung function to determine change in magnitude and significance of associations. In all analyses, subjects with missing data for any included covariates were excluded.
Two secondary analyses were performed. We evaluated the association of the genotype with postbronchodilator lung function by linear regression limited to asthmatic subjects as the bronchodilator response was not measured in controls. We also investigated the association between the at-risk polymorphism and FEV 1 /FVC ratio by age in subjects with asthma as a secondary analysis. Age was categorized as <12 or ≥12 years of age. 
| RESULTS
Subject characteristics of the overall study sample and divided by those with and without asthma are presented in Table 1 . The mean age of the study population was 13AE3.45 years, and majority of participants were Puerto Rican (40.1%) or Mexican (38.2%). There were no differences between asthmatic and control subjects in the distribution of the at-risk genotype. Similarly, there were no difference in SES, and smoke exposure during the postnatal period up to 6 years old. However, asthmatic subjects had more Puerto Rican and less
Mexican subjects than non-asthmatic subjects, a greater proportion of African ancestry, and a greater proportion of subjects who were exposed to in utero tobacco exposure than non-asthmatic subjects, respectively. As expected, all lung function measures were lower in asthmatic subjects than non-asthmatic subjects (Table 1) . Absolute measurements of pulmonary function in all subjects based on their asthma and genotype status are presented in Table S1 .
Initial regression analysis of all subjects (asthmatic and non-asthmatic subjects combined) revealed no association of the rs2227631
gain-of-function genotype on the per cent predicted FEV 1 or FVC ( To determine whether these associations were mitigated by other factors known to increase PAI-1 levels (secondhand smoke exposure (pre-and postnatal), obesity, and pulmonary illnesses prior to 2 years old), we added these variables individually and then in combination to the base model. None of these associations individually or in combination significantly changed the effect size or significance of the association of the at-risk polymorphism on FEV 1 /FVC ( 
| DISCUSSION
We recently demonstrated that a gain-of-function polymorphism in the PAI-1 promoter region leads to an increased risk of asthma and reduced lung function in asthmatic subjects in the context of severe early life lower respiratory infection. 10 Our group, among others, has also found that PAI-1 is associated with altered lung function and increased odds of hospitalization/ER utilization in subjects with asthma. 10 gain-of-function mutation was associated with FEV 1 /FVC ratio and airway obstruction in subjects with asthma, but not in healthy control subjects. Moreover, subjects with the at-risk polymorphism were at a 39% increased odds for airway obstruction (FEV 1 /FVC <80% predicted) compared to asthmatic subjects without the at-risk genotype. This is relevant because a decreased FEV 1 /FVC will alter a child's clinical care by modifying the category they are placed within stepped therapy guidelines.
While the majority of subjects had normal per cent predicted pulmonary function, the genotype was associated with a decrease in per cent predicted FEV 1 /FVC ratio in both the pre-and postbronchodilator analysis. The fact that the association persists in postbronchodilator lung function would suggest that any genotypeassociated airflow limitation has a fixed component. We also found that the effect is greater in younger children. However, our analysis suggests that the lack of significance for the effect in children 12 years of age an older may be due to an increasing effect of obesity (which also increases PAI-1) in this age group (b=À3.29 in children ≥12 years of age compared with À0.21 in children <12 years of age). Therefore, the effects of obesity may overshadow the independent effects of the at-risk polymorphism in the older age group.
Based on these results, we believe that the PAI-1 polymorphism serves as a risk factor for airway obstruction in patients with asthma, particularly in children <12 years of age.
Our study is not able to determine causality or mechanism.
However, there are different ways that PAI-1 may affect lung function. Coagulation and fibrin pathways are activated in non-exacerbated asthmatics, including higher concentration of PAI-1 in circulating blood. [32] [33] [34] Over-production of PAI-1, in cooperation with other coagulation factors activated at baseline in asthmatics, may move the haemostatic equilibrium to impaired fibrinolysis.
Because the fibrinolytic system is important during repair processes, reduced fibrinolytic capacity may contribute to the impaired restoration of inflamed lung tissue. However, PAI-1 may also enhance airway inflammation by activation of G-protein-coupled protease-activated receptors (PARs) expressed on smooth muscle and epithelial airway cells. 35 Activation of these may lead to an increase in inflammatory cytokine profile including interleukin-6 and platelet derived growth factor, furthering airway inflammation and airway structural change. 34 We are not able to differentiate whether these findings are secondary to systemic effects of PAI-1 itself or due to a localized effect due to increased airway expression. Thus, further work is needed to further elucidate the mechanism behind this outcome.
Plasminogen activator inhibitor 1 is secreted by both airway epithelial cells 36 and human mast cells upon stimulation. 37 Plasminogen activator is essential in regulating fibrotic processes and is inhibited by the PAIs, in particular PAI-1. 13 In the airway, overexpression of PAI-1 leads to increased lung injury and deposition of extracellular matrix. 13, 14 Latino Americans have approximately 65% higher PAI-1 protein levels compared to African Americans and non-Latino Caucasians. 23, 24 Therefore, a gain-of-function polymorphism has even greater potential to impact lung function in Latino populations.
However, these findings were replicated in the African American SAPPHIRE cohort, suggesting that these findings are not specific to Latinos, and potentially generalizable.
Furthermore, environmental factors common in underserved Latino populations, including obesity and tobacco exposure, [16] [17] [18] 38 also play a key role in regulating PAI-1 levels. 15, [19] [20] [21] [22] [39] [40] [41] [42] [43] Adipose tissue, particularly visceral adipose tissue, produces PAI-1, and obesity is associated with increased circulating PAI-1 levels. 15, 21, [39] [40] [41] Sputum PAI-1 levels increase in subjects with asthma during acute viral respiratory illnesses, including influenza A viral infection leading to subsequent lung injury. 19, 20 Smoking (passive and active) as well as nicotine exposure is associated with increased PAI-1 levels, particularly in individuals with PAI-1 gain-of-function mutations. 22, 42, 44, 45 As these PAI-1 promoting exposures are common, we expected them to drive much of the association of the gain-of-function mutation and lung function. We found that the PAI-1 polymorphism was still associated with airway obstruction after controlling these factors. This finding implies that ongoing low-grade inflammation associated with asthma may be equally important in the effect of this polymorphism on lung function. This hypothesis may also have relevance for the finding of an interaction between genotype and asthma status.
There are several limitations to this study. Fewer subjects without asthma had pulmonary function available; however, there were no systematic differences in demographic features such as age, race, sex, and SES compared to controls without pulmonary function. Furthermore, all unstratified and stratified analyses controlled for key covariates. Also, while an in-depth analysis of non-asthmatics alone was not possible, determination of effect modification by asthma status was our primary objective and we were powered for this. Secondly, any individuals with the at-risk polymorphism, either heterozygotes or homozygotes, were combined for purposes of analysis to increase the stability of the estimates. In a secondary analysis, we carried out a sensitivity analysis with AA and AG separately and demonstrated a significant dose effect for both genotypes, making the combined estimate a conservative one. Both the SNP we looked at, rs2227631, and a insertion/deletion variant in the PAI-1 promoter site (4G/5G), which is also associated with PAI-1 levels, are in strong linkage disequilibrium (D'=0.97). 46 We did not sequence the 4G/5G site, but the degree of LD would make it difficult to determine which of the two is functional even if we had done so. However, the s2227631 locus has been found to be the variant most closely associated with PAI-1 levels on GWAS 47 and is used as a proxy for the 4G/5G site on arrays. Other limitations include that we did not evaluate mediation of genotype effect by other environmental factors, such as air pollution and allergen exposure. We had not focused on these factors as they are not described as major contributors to PAI-1 level. This will be an area for future study. The exposures of early life respiratory illness and maternal smoking were self-reported. While these exposures may be underreported due to reluctance to admit smoking in pregnancy or in the home, underreporting should not vary by genotype. Any misclassification would bias results towards the null hypothesis, making our findings even more robust. There were more females, slightly older ages, and slightly lower levels of African ancestry in the healthy control group; however, these differences are small in magnitude and were controlled for in our analysis both directly by ancestry variables and indirectly using per cent predicted lung function. Lastly, this study was cross-sectional, and therefore, we do not know how elevated PAI-1 levels affect lung function trajectory or if a critical window exists in early life where these levels are most influential.
In summary, we found that the association of a gain-of-function polymorphism in the PAI-1 promoter region, rs2227631, with lung function is modified by asthma status. The polymorphism is associated with decreased FEV 1 /FVC ratio and increased prevalence of airway obstruction in Latino and African American subjects with asthma, but it has no effect in healthy controls. We further found that these associations persisted after accounting for common and chronic exposures such as smoking and obesity which increase PAI-1 levels. These findings suggest that this common genetic variant may be an important modifier of airway obstruction associated with asthmatic airway inflammation. Further studies should explore the trajectory of lung function change over time in older adults with the genotype and a longer duration of smoking and obesity.
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